PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy.

Autor: Gonzalez-Melero L; NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain., Santos-Vizcaino E; NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, Madrid, Spain., Varela-Calvino R; Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Santiago de Compostela, Santiago, Spain., Gomez-Tourino I; Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago, Spain.; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain., Asumendi A; Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain.; Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940, Leioa, Spain., Boyano MD; Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain.; Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940, Leioa, Spain., Igartua M; NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain. manoli.igartua@ehu.eus.; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain. manoli.igartua@ehu.eus.; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, Madrid, Spain. manoli.igartua@ehu.eus., Hernandez RM; NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain. rosa.hernandez@ehu.eus.; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain. rosa.hernandez@ehu.eus.; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, Madrid, Spain. rosa.hernandez@ehu.eus.
Jazyk: angličtina
Zdroj: Drug delivery and translational research [Drug Deliv Transl Res] 2024 Oct; Vol. 14 (10), pp. 2788-2803. Date of Electronic Publication: 2024 Mar 01.
DOI: 10.1007/s13346-024-01557-2
Abstrakt: Melanoma is the main cause of death among skin cancers and its incidence worldwide has been experiencing an appalling increase. However, traditional treatments lack effectiveness in advanced or metastatic patients. Immunotherapy, meanwhile, has been shown to be an effective treatment option, but the rate of cancers responding remains far from ideal. Here we have developed a personalized neoantigen peptide-based cancer vaccine by encapsulating patient derived melanoma neoantigens in polyethylenimine (PEI)-functionalised poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) and coating them with polyinosinic:polycytidylic acid (poly(I:C)). We found that PLGA NPs can be effectively modified to be coated with the immunoadjuvant poly(I:C), as well as to encapsulate neoantigens. In addition, we found that both dendritic cells (DCs) and lymphocytes were effectively stimulated. Moreover, the developed NP was found to have a better immune activation profile than NP without poly(I:C) or without antigen. Our results demonstrate that the developed vaccine has a high capacity to activate the immune system, efficiently maturing DCs to present the antigen of choice and promoting the activity of lymphocytes to exert their cytotoxic function. Therefore, the immune response generated is optimal and specific for the elimination of melanoma tumour cells.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: